JP2016531156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531156A5 JP2016531156A5 JP2016542823A JP2016542823A JP2016531156A5 JP 2016531156 A5 JP2016531156 A5 JP 2016531156A5 JP 2016542823 A JP2016542823 A JP 2016542823A JP 2016542823 A JP2016542823 A JP 2016542823A JP 2016531156 A5 JP2016531156 A5 JP 2016531156A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- peptide
- group
- amino acid
- relaxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 55
- 229940124597 therapeutic agent Drugs 0.000 claims 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 108090000103 Relaxin Proteins 0.000 claims 17
- 102000003743 Relaxin Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 150000002632 lipids Chemical class 0.000 claims 11
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 8
- -1 fatty diacids Chemical class 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 7
- 230000006229 amino acid addition Effects 0.000 claims 5
- 229920000151 polyglycol Polymers 0.000 claims 5
- 239000010695 polyglycol Substances 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 claims 4
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 3
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims 3
- 229930182558 Sterol Natural products 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003827 glycol group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 150000003432 sterols Chemical class 0.000 claims 3
- 235000003702 sterols Nutrition 0.000 claims 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 2
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 239000004380 Cholic acid Substances 0.000 claims 2
- 108010011459 Exenatide Proteins 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 claims 2
- 102400000321 Glucagon Human genes 0.000 claims 2
- 108060003199 Glucagon Proteins 0.000 claims 2
- 102100040890 Glucagon receptor Human genes 0.000 claims 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 claims 2
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 claims 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 150000008431 aliphatic amides Chemical class 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 2
- 229960002471 cholic acid Drugs 0.000 claims 2
- 235000019416 cholic acid Nutrition 0.000 claims 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 229940030606 diuretics Drugs 0.000 claims 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- 229940125542 dual agonist Drugs 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 229960001519 exenatide Drugs 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 150000002191 fatty alcohols Chemical class 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 2
- 229960004666 glucagon Drugs 0.000 claims 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
- 108700041144 Angiopoietin-Like Protein 8 Proteins 0.000 claims 1
- 102100034604 Angiopoietin-like protein 8 Human genes 0.000 claims 1
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 1
- 102100034120 Golgin subfamily A member 6A Human genes 0.000 claims 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims 1
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 claims 1
- 101000998777 Homo sapiens Early placenta insulin-like peptide Proteins 0.000 claims 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 1
- 101100397008 Homo sapiens INSL3 gene Proteins 0.000 claims 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 101000998810 Homo sapiens Insulin-like peptide INSL6 Proteins 0.000 claims 1
- 108700012441 IGF2 Proteins 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108700014400 Leydig insulin-like Proteins 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 102400000319 Oxyntomodulin Human genes 0.000 claims 1
- 101800001388 Oxyntomodulin Proteins 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 102000044162 human IGF1 Human genes 0.000 claims 1
- 102000055043 human INSL4 Human genes 0.000 claims 1
- 102000050306 human INSL6 Human genes 0.000 claims 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims 1
- 229920001748 polybutylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 108010087851 prorelaxin Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877799P | 2013-09-13 | 2013-09-13 | |
| US61/877,799 | 2013-09-13 | ||
| US201361917816P | 2013-12-18 | 2013-12-18 | |
| US61/917,816 | 2013-12-18 | ||
| PCT/US2014/055457 WO2015038938A1 (en) | 2013-09-13 | 2014-09-12 | Modified therapeutic agents and compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019197971A Division JP2020063249A (ja) | 2013-09-13 | 2019-10-30 | 修飾された治療剤、及びその組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531156A JP2016531156A (ja) | 2016-10-06 |
| JP2016531156A5 true JP2016531156A5 (https=) | 2017-09-07 |
| JP6822839B2 JP6822839B2 (ja) | 2021-01-27 |
Family
ID=52666336
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542823A Active JP6822839B2 (ja) | 2013-09-13 | 2014-09-12 | 修飾された治療剤、及びその組成物 |
| JP2019197971A Pending JP2020063249A (ja) | 2013-09-13 | 2019-10-30 | 修飾された治療剤、及びその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019197971A Pending JP2020063249A (ja) | 2013-09-13 | 2019-10-30 | 修飾された治療剤、及びその組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10286078B2 (https=) |
| EP (1) | EP3043824B1 (https=) |
| JP (2) | JP6822839B2 (https=) |
| KR (1) | KR102302634B1 (https=) |
| CN (1) | CN105792851B (https=) |
| AU (1) | AU2014318579A1 (https=) |
| CA (1) | CA2924109A1 (https=) |
| ES (1) | ES2927607T3 (https=) |
| WO (1) | WO2015038938A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105792851B (zh) | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
| JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー／エス | 極性の組換え延長部を有するインスリン |
| WO2016196017A1 (en) | 2015-06-04 | 2016-12-08 | Antriabio, Inc. | Amine pegylation methods for the preparation of site-specific protein conjugates |
| WO2016205488A1 (en) | 2015-06-17 | 2016-12-22 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| CN106554404B (zh) * | 2015-09-25 | 2020-11-20 | 博瑞生物医药（苏州）股份有限公司 | 艾塞那肽修饰物及其用途 |
| CN108136043B (zh) | 2015-10-01 | 2022-09-06 | 诺和诺德股份有限公司 | 蛋白质缀合物 |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| CN108697768B (zh) | 2015-12-23 | 2022-07-22 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法 |
| CN107325168B (zh) * | 2016-06-28 | 2018-10-30 | 江苏豪思生物科技有限公司 | 一种经修饰的生长分化因子及其制备方法和应用 |
| CN106361405B (zh) * | 2016-10-09 | 2017-07-28 | 上海岐华医疗科技有限公司 | 改进的超声外科手术系统 |
| WO2018069442A1 (en) | 2016-10-12 | 2018-04-19 | University Of Copenhagen | Peptide dual agonists of gipr and glp2r |
| AU2017358289C1 (en) | 2016-11-10 | 2025-05-08 | Yuhan Corporation | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
| CN106432471B (zh) * | 2016-12-14 | 2019-12-03 | 江苏师范大学 | 一种新型非洲爪蟾胰高血糖素样肽-1(glp-1)缀合肽及其应用 |
| CN108299553B (zh) * | 2017-01-13 | 2021-07-16 | 博瑞生物医药（苏州）股份有限公司 | 胃泌酸调节素修饰物 |
| CN110637027B (zh) | 2017-02-08 | 2024-08-30 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
| CN108619490A (zh) * | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | 一种长效化突变的人源成纤维生长因子的新用途 |
| AU2018237139A1 (en) * | 2017-03-22 | 2019-10-17 | The Regents Of The University Of California | Modified oligonucleotides and therapeutic uses thereof |
| CN110505885A (zh) | 2017-04-05 | 2019-11-26 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物 |
| CN110709520B (zh) | 2017-04-21 | 2024-04-05 | 株式会社柳韩洋行 | 用于产生双功能蛋白质及其衍生物的方法 |
| WO2019072963A1 (en) | 2017-10-12 | 2019-04-18 | University Of Copenhagen | POLYTHERAPY FOR THE TREATMENT OF BONE DISEASES |
| WO2019085773A1 (zh) * | 2017-11-06 | 2019-05-09 | 中山大学 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化 |
| MA52994A (fr) * | 2018-01-31 | 2021-05-05 | Sanofi Sa | Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique |
| CN110568112A (zh) * | 2018-06-05 | 2019-12-13 | 北京华金瑞清生物医药技术有限公司 | 一种直接检测艾塞那肽融合蛋白的方法 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| CN111662373B (zh) * | 2019-03-05 | 2024-05-14 | 广东东阳光药业股份有限公司 | 一种多肽分子及其应用 |
| US20200318113A1 (en) * | 2019-03-05 | 2020-10-08 | MiRagen Therapeutics, Inc. | Polynucleotide conjugates and uses thereof |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| AU2020397917A1 (en) * | 2019-12-04 | 2022-06-23 | The Scripps Research Institute | GLP2 receptor agonists and methods of use |
| WO2021139763A1 (zh) * | 2020-01-08 | 2021-07-15 | 上海翰森生物医药科技有限公司 | Fgf21突变体蛋白及其融合蛋白 |
| CN115279392A (zh) * | 2020-01-20 | 2022-11-01 | 鲁达库尔公司 | 治疗trpv1活性介导疾病的药物组合物 |
| IL297951A (en) * | 2020-05-08 | 2023-01-01 | Harvard College | Engineered relaxins and methods of use thereof |
| CN114075276A (zh) * | 2020-08-17 | 2022-02-22 | 成都奥达生物科技有限公司 | 一种长效松弛素2类似物 |
| CN114478709A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效肝炎病毒进入抑制剂 |
| TW202241491A (zh) * | 2020-12-16 | 2022-11-01 | 丹麥商西蘭製藥公司 | Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物 |
| EP4316495A4 (en) * | 2021-03-25 | 2025-12-31 | Aptacure Therapeutics Ltd | CONJUGATE OF NUCLEIC ACID MOLECULE HAVING A PROLONGED IN VIVO HALF-LIFE |
| EP4337680A1 (en) * | 2021-05-11 | 2024-03-20 | Cytoki Pharma ApS | Therapeutic derivatives of interleukin-22 |
| MX2023014771A (es) | 2021-06-09 | 2024-03-19 | Scripps Research Inst | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. |
| TW202317645A (zh) * | 2021-07-05 | 2023-05-01 | 大陸商上海翰森生物醫藥科技有限公司 | 一種融合蛋白及其醫藥用途 |
| WO2023086913A2 (en) | 2021-11-11 | 2023-05-19 | Tectonic Therapeutic, Inc. | Relaxin-2 fusion protein analogs and methods of using same |
| EP4705331A1 (en) * | 2023-05-01 | 2026-03-11 | Neuraly Inc. | Glucagon-like peptide-1 receptor agonist variants and methods thereof |
| KR20260035823A (ko) | 2023-05-18 | 2026-03-13 | 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 | 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법 |
| US20250345398A1 (en) * | 2024-03-19 | 2025-11-13 | Bioxel, Inc. | Agents and methods for treating disease |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3887699A (en) | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| DE3413608A1 (de) | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| IT1247472B (it) | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| EP0707650B1 (en) | 1993-06-21 | 2003-05-21 | Genentech, Inc. | Process for producing human relaxin |
| CZ287945B6 (cs) | 1993-09-17 | 2001-03-14 | Novo Nordisk A/S | Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| DK0779806T3 (da) | 1994-09-09 | 2000-11-27 | Takeda Chemical Industries Ltd | Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid |
| ATE212545T1 (de) | 1995-03-28 | 2002-02-15 | Fidia Advanced Biopolymers Srl | Nanosphären mit einem biokompatiblen polysaccharid |
| NZ310644A (en) | 1995-06-07 | 1999-08-30 | Alkermes Inc | Composition for sustained release of human growth hormone |
| US5911997A (en) | 1995-06-07 | 1999-06-15 | Connetics Corporation | Relaxin-like factor and methods and uses thereof |
| US5811395A (en) * | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| DE19822820A1 (de) * | 1998-05-20 | 1999-11-25 | Biotechnolog Forschung Gmbh | Pharmazeutisches Präparat zur Wundbehandlung |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| JP2004535401A (ja) | 2001-05-21 | 2004-11-25 | ネクター セラピューティックス | 化学的に改変されたインスリンの肺投与 |
| AU2003249317B2 (en) | 2002-07-19 | 2007-08-02 | Institute Of Materials Research And Engineering | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| WO2004100997A2 (en) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Spacer moiety for poly(ethylene glycol) -modified peptides |
| US20060183667A1 (en) | 2003-07-11 | 2006-08-17 | Novo Nordisk A/S | Stabilised insulin compositions |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| EP1576952A1 (en) | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
| WO2005118620A2 (en) | 2004-05-27 | 2005-12-15 | New York University | Methods for preparing internally constraied peptides and peptidomimetics |
| WO2006066258A2 (en) * | 2004-12-17 | 2006-06-22 | Neose Technologies, Inc. | Lipoconjugation of peptides |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20080305519A1 (en) | 2006-02-23 | 2008-12-11 | Qing Lin | Biochemical method for specific protein labeling |
| KR20080113226A (ko) * | 2006-03-16 | 2008-12-29 | 더 스크립스 리서치 인스티튜트 | 비천연 아미노산 페닐셀레노시스테인을 함유하는 단백질의 유전자적으로 프로그램된 발현 |
| KR20090005329A (ko) * | 2006-03-20 | 2009-01-13 | 머크 앤드 캄파니 인코포레이티드 | 뉴로메딘 ｕ 수용체 효능제 및 이의 용도 |
| WO2007109354A2 (en) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| AU2007267833B2 (en) | 2006-05-26 | 2012-07-26 | Amylin Pharmaceuticals, Llc | Composition and methods for treatment of congestive heart failure |
| EP2069502B1 (en) | 2006-09-27 | 2014-02-26 | Novo Nordisk A/S | Method for making maturated insulin polypeptides |
| KR20090091145A (ko) * | 2006-10-27 | 2009-08-26 | 웨이-치앙 션 | 지질화된 인터페론 및 이의 용도 |
| JP4616237B2 (ja) | 2006-11-07 | 2011-01-19 | 日本電信電話株式会社 | シリコン化合物薄膜の形成方法 |
| CN105061577A (zh) | 2006-12-14 | 2015-11-18 | 爱勒让治疗公司 | 双巯基大环化系统 |
| US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| ES2398310T3 (es) | 2007-02-23 | 2013-03-15 | Aileron Therapeutics, Inc. | Péptidos macrocíclicos unidos a triazol |
| US8420598B2 (en) | 2007-04-20 | 2013-04-16 | B & L Delipharm Corp. | Mono modified exendin with polyethylene glycol or its derivatives and uses thereof |
| AU2008266753A1 (en) | 2007-06-20 | 2008-12-24 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | ApoA-1 peptide mimetics |
| KR20100126361A (ko) | 2008-02-08 | 2010-12-01 | 에일러론 테라퓨틱스 인코포레이티드 | 치료용 펩티드유사 거대고리 |
| WO2009126292A2 (en) | 2008-04-08 | 2009-10-15 | Aileron Therapeutics, Inc. | Biologically active peptidomimetic macrocycles |
| US20110144303A1 (en) | 2008-04-08 | 2011-06-16 | Aileron Therapeutics, Inc. | Biologically Active Peptidomimetic Macrocycles |
| US8586707B2 (en) | 2008-09-16 | 2013-11-19 | The Research Foundation Of State University Of New York | Stapled peptides and method of synthesis |
| CN102884074A (zh) | 2008-09-22 | 2013-01-16 | 爱勒让治疗公司 | 拟肽大环化合物 |
| CN102203126A (zh) | 2008-09-22 | 2011-09-28 | 爱勒让治疗公司 | 用于制备纯化的多肽组合物的方法 |
| ES2666458T3 (es) | 2008-09-22 | 2018-05-04 | Aileron Therapeutics, Inc. | Macrociclos peptidomiméticos |
| EP2352507A4 (en) | 2008-11-24 | 2012-04-25 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES |
| WO2010083347A2 (en) | 2009-01-14 | 2010-07-22 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CA2748314C (en) * | 2009-02-03 | 2018-10-02 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| MX2012003939A (es) | 2009-09-30 | 2012-07-30 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
| US20110223149A1 (en) | 2009-10-14 | 2011-09-15 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP2512518A1 (en) | 2009-12-16 | 2012-10-24 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| US20110243943A1 (en) * | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Treatment using relaxin-fusion proteins with extended in vivo half-lives |
| BR112013000603A2 (pt) | 2010-07-09 | 2016-07-05 | Jv Bio Srl | anticorpos conjugados com lipídios |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| MA34521B1 (fr) * | 2010-08-17 | 2013-09-02 | Ambrx Inc | Polypeptides de relaxine modifiés et leurs utilisations |
| US9567386B2 (en) * | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| US9029332B2 (en) | 2010-12-15 | 2015-05-12 | The Research Foundation For The State University Of New York | Cross-linked peptides and proteins, methods of making same, and uses thereof |
| US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| SG191252A1 (en) | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| CA2834657A1 (en) | 2011-04-29 | 2012-11-01 | Kinemed, Inc. | Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents |
| EP2726502A1 (en) | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin fusion polypeptides and uses thereof |
| JP2014529293A (ja) | 2011-07-08 | 2014-11-06 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | レラキシンを放出する融合タンパク質およびその使用 |
| AR088392A1 (es) | 2011-10-18 | 2014-05-28 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CN117462693A (zh) * | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| CN105792851B (zh) * | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| MA41794A (fr) | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
-
2014
- 2014-09-12 CN CN201480062386.7A patent/CN105792851B/zh active Active
- 2014-09-12 US US14/917,689 patent/US10286078B2/en active Active
- 2014-09-12 JP JP2016542823A patent/JP6822839B2/ja active Active
- 2014-09-12 CA CA2924109A patent/CA2924109A1/en not_active Abandoned
- 2014-09-12 EP EP14843357.6A patent/EP3043824B1/en active Active
- 2014-09-12 WO PCT/US2014/055457 patent/WO2015038938A1/en not_active Ceased
- 2014-09-12 KR KR1020167009482A patent/KR102302634B1/ko active Active
- 2014-09-12 AU AU2014318579A patent/AU2014318579A1/en not_active Abandoned
- 2014-09-12 ES ES14843357T patent/ES2927607T3/es active Active
-
2019
- 2019-05-07 US US16/405,594 patent/US10987427B2/en active Active
- 2019-10-30 JP JP2019197971A patent/JP2020063249A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531156A5 (https=) | ||
| JP6987993B2 (ja) | インクレチン類似体およびその使用 | |
| JP6026993B2 (ja) | 新規のグルカゴンアナログ | |
| JP6121330B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| AU2014241743B2 (en) | Insulin-incretin conjugates | |
| CN103957927B (zh) | 呈现糖皮质激素受体活性的胰高血糖素超家族肽 | |
| AU2018338184B2 (en) | Long-acting co-agonists of the glucagon and GLP-1 receptors | |
| JP6050746B2 (ja) | Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド | |
| CA2797095A1 (en) | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | |
| JP2013533849A5 (https=) | ||
| CA2965560A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| US20150111246A1 (en) | Site-specific enzymatic modification of exendins and analogs thereof | |
| JP2014525901A5 (https=) | ||
| JP2014510739A (ja) | 新規のグルカゴン類似体 | |
| JP2017536343A5 (https=) | ||
| WO2013148966A1 (en) | Transmucosal delivery of engineered polypeptides | |
| CN115697414A (zh) | Glp1r激动剂nmdar拮抗剂缀合物 | |
| JP2007537149A (ja) | 長時間作用性のグルカゴン様ペプチド−１類似体 | |
| Madsen et al. | Long-Acting Lipidated Analogue of Human Pancreatic Polypeptide Is Slowly Released into Circulation | |
| EA043728B1 (ru) | Аналоги инкретина и их применение | |
| HK40012348B (zh) | 用於预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物 | |
| HK1183241A (en) | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |